XML 40 R30.htm IDEA: XBRL DOCUMENT
v3.23.2

Intangible Assets (Tables) | 6 Months Ended
--- | ---
Jul. 01, 2023
Goodwill and Intangible Assets Disclosure [Abstract] |
Schedule of Intangible Assets | Intangible assets as of July 1, 2023 and December 31, 2022 consist of the following (in $000’s):
| July 1, 2023 |  | December 31, 2022
Patent and domains | $ | 4 |  |  | $ | 4 |
Soin intangibles * | $ | 19,293 |  |  | $ | 19,293 |
Computer software | — |  |  | 3,563 |
Intangible assets from discontinued operations | — |  |  | 735 |
Intangible assets | 19,297 |  |  | 23,595 |
Less accumulated amortization | (726) |  |  | (3,563) |
Total intangible assets | $ | 18,571 |  |  | $ | 20,032 |
*The Soin intangibles acquired by the Company consist of the following: 1.Three pending patents related to the methods of using low-dose Naltrexone to treat chronic pain; 2.Final formula for Naltrexone; and 3.Orphan drug designation as approved by the FDA.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2 + Details
Name: | us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration